SƠN TĨNH ĐIỆN

• 

  Xử lý bề mặt sơn

  Xử lý bề mặt sơn giúp đảm bảo tạo cho bột sơn có độ bám dính tốt hơn, lên màu đẹp và có độ bền chắc cao hơn.
• 

  Phun sơn

  Quá trình phun sơn tĩnh điện sẽ được diễn ra trong buồng sơn. Buồng phun sơn không chỉ có vai trò đảm bảo sơn không phát tán nhiều ra không khí mà quan trọng hơn, nó giúp thu hồi lượng bột sơn dư để tái sử dụng cho lần sơn tiếp theo.
• 

  Sấy khô

  Sau khi phun sơn, sản phẩm được đưa vào lò sấy, sấy ở nhiệt độ 180 độ C – 200 độ C trong 10 phút. Lò có nguồn nhiệt chính từ tia hồng ngoại hoặc burner với nguyên liệu đốt là khí gas.
• 

  Kiểm tra, đóng gói

  Sau khi hoàn thành sấy khô, chúng ta tiến hành kiểm tra thành phẩm trước khi đóng gói và chuyển đi các kênh phân phối.

Along with their colleagues, Dr. Jonathan Loree, a medical oncologist and assistant professor at the University of British Columbia in Vancouver in Canada and Dr. Kanwal Raghav, an associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston analyzed 230 oncology clinical trials. These trials took place between 2008–2018 and resulted in the Food and Drug Administration (FDA) approving cancer drugs.

They found that only 145 (63%) of the 230 trials, included any information about the participant’s race. More specifically, only 18 trials (7.8%) gave a breakdown of the participants by the “four major races in the United States (white, Asian, Black, and Hispanic)” as the authors put it.
On average, 76.3% of the participants were white, 18.3% Black, 3.1% Asian, and 6.1% Hispanic. In the period that the authors looked at, these percentages changed only marginally.

Along with their colleagues, Dr. Jonathan Loree, a medical oncologist and assistant professor at the University of British Columbia in Vancouver in Canada and Dr. Kanwal Raghav, an associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston analyzed 230 oncology clinical trials. These trials took place between 2008–2018 and resulted in the Food and Drug Administration (FDA) approving cancer drugs.

They found that only 145 (63%) of the 230 trials, included any information about the participant’s race. More specifically, only 18 trials (7.8%) gave a breakdown of the participants by the “four major races in the United States (white, Asian, Black, and Hispanic)” as the authors put it.
On average, 76.3% of the participants were white, 18.3% Black, 3.1% Asian, and 6.1% Hispanic. In the period that the authors looked at, these percentages changed only marginally.

Along with their colleagues, Dr. Jonathan Loree, a medical oncologist and assistant professor at the University of British Columbia in Vancouver in Canada and Dr. Kanwal Raghav, an associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston analyzed 230 oncology clinical trials. These trials took place between 2008–2018 and resulted in the Food and Drug Administration (FDA) approving cancer drugs.